Humalog (Insulin Lispro) Humalog 2022 sales: $2.060 billion Company/Developer: Eli Lilly Date of first FDA approval: June 14, 1996 Indications Humalog is FDA-approved for: Humalog is a fast-acting human insulin analog designed to enhance glycemic control in both adult and pediatric patients with diabetes mellitus types 1 and 2
Reference 3 in the editorial, Wang et al, is a much more reliable type of study, and not only does not show an effect but suggested protection: semaglutide compared with non-GLP1R agonist anti-obesity medications was associated with lower risk for incident (HR = 0.27, 95% CI = 0.200.320.600.36) and recurrent (HR = 0.44, 95% CI = 0.320.60) suicidal ideation, consistent across sex, age and ethnicity stratification
Research published in the Journal of Clinical Investigation Insight confirmed that this PHB-ANXA2 complex exists in both mouse and human white fat vasculature, which was a critical finding for translational relevance
If you're on medications known to cause pigmentation and you're concerned about gum discoloration, talk to your doctor